A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults

Critical Care Medicine

Volumn 43, Issue 8, 2015, Pages 1622-1629

  Gattas, David J ^a,b   Rajbhandari, Dorrilyn ^a,b   Bradford, Celia ^c   Buhr, Heidi ^a   Lo, Serigne ^b   Bellomo, Rinaldo ^d,e  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^c ROYAL NORTH SHORE HOSPITAL   (Australia)

^d Australian and New Zealand Intensive Care Research Centre   (Australia)

^e AUSTIN HOSPITAL   (Australia)

Author keywords

Continuous renal replacement therapy; Intensive care; Randomized controlled trial; Regional citrate anticoagulation

Indexed keywords

CALCIUM; CITRIC ACID; HEPARIN; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; PROTAMINE; ANTICOAGULANT AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD FLOW VELOCITY; COMPARATIVE STUDY; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DIALYSIS CATHETER; DRUG WITHDRAWAL; EMERGENCY WARD; FEMALE; FOLLOW UP; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; APACHE; BLOOD; CLINICAL TRIAL; CRITICAL ILLNESS; INTENSIVE CARE UNIT; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; RENAL REPLACEMENT THERAPY; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; APACHE; CALCIUM; CITRIC ACID; CRITICAL ILLNESS; FEMALE; HEPARIN; HUMANS; INTENSIVE CARE UNITS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MIDDLE AGED; PROTAMINES; RENAL REPLACEMENT THERAPY; TIME FACTORS;

EID: 84942512053     PISSN: 00903493     EISSN: 15300293     Source Type: Journal    
DOI: 10.1097/CCM.0000000000001004     Document Type: Article

References (20)

1. Joannidis M, Oudemans-van Straaten HM: Clinical review: Patency of the circuit in continuous renal replacement therapy. Crit Care 2007; 11:218
2. Fealy N, Baldwin I, Bellomo R: The effect of circuit down-time on uraemic control during continuous veno-venous haemofiltration. Crit Care Resusc 2002; 4:266-270
3. Kidney Disease Improving Global Outcomes (KDIGO): Section 5: Dialysis interventions for treatment of AKI. Kidney Int Suppl 2012; 2:89-115
4. Oudemans-van Straaten HM, Wester JP, de Pont AC, et al: Anticoagulation strategies in continuous renal replacement therapy: Can the choice be evidence based? Intensive Care Med 2006; 32:188-202
5. The RENAL Replacement Therapy Study Investigators: Intensity of continuous renal-replacement therapy in critically ill patients. New Engl J Med 2009; 361:1627-1638
6. Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, et al Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial 2011;15:556-564
7. Moor MB, Kruse A, Uehlinger DE, et al: Arterial stiffness depends on serum ionized calcium levels during dialysis with regional citrate anticoagulation. Artif Organs 2013; 37:467-474
8. Hoffmann TC, Glasziou PP, Boutron I, et al: Better reporting of interventions: Template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014; 348:g1687
9. Box-Steffensmeier JM, De Boef S: Repeated events survival models: The conditional frailty model. Stat Med 2006; 25:3518-3533
10. Monchi M, Berghmans D, Ledoux D, et al: Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study. Intensive Care Med 2004; 30:260-265
11. Kutsogiannis DJ, Gibney RT, Stollery D, et al: Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67:2361-2367
12. Hetzel GR, Schmitz M, Wissing H, et al: Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: A prospective randomized multicentre trial. Nephrol Dial Transplant 2011; 26:232-239
13. Schilder L, Nurmohamed SA, Bosch FH, et al; CASH study group: Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: A multi-center randomized clinical trial. Crit Care 2014; 18:472
14. Fealy N, Baldwin I, Johnstone M, et al: A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs 2007; 30:301-307
15. Betjes MG, van Oosterom D, van Agteren M, et al: Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: Similar hemofilter survival but significantly less bleeding. J Nephrol 2007; 20:602-608
16. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, et al: Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med 2009; 37:545-552
17. Tillman J: Heparin versus citrate for anticoagulation in critically ill patients treated with continuous renal replacement therapy. Nurs Crit Care 2009; 14:191-199
18. Wu MY, Hsu YH, Bai CH, et al: Regional citrate versus heparin anticoagulation for continuous renal replacement therapy: A meta-analysis of randomized controlled trials. Am J Kidney Dis 2012; 59:810-818
19. Zhang Z, Hongying N: Efficacy and safety of regional citrate anticoagulation in critically ill patients undergoing continuous renal replacement therapy. Intensive Care Med 2012; 38:20-28
20. Liao YJ, Zhang L, Zeng XX, et al: Citrate versus unfractionated heparin for anticoagulation in continuous renal replacement therapy. Chin Med J (Engl) 2013; 126:1344-1349